THE RECOMBINANT ANTIGENS FOR VACCINES FOR THE TREATMENT OF PAPILLOMAVIRUS (REVIEW)
Two licensed vaccines Gardasil and Cervarix, containing main capsid protein L1 virus-like particles antigen, are used for prevention of diseases associated with human papilloma virus. L1 cannot provide protection against all pathogenic strains of HPV, shows low efficacy in middle and old age vaccina...
Saved in:
| Main Author: | M. A. Zhuchenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/227 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MODERN ASPECTS OF HUMAN PAPILLOMAVIRUS VACCINATION
by: O. S. Alyautdina, et al.
Published: (2018-09-01) -
Optimizing the production of recombinant human papilloma virus type 52 major capsid protein L1 in Hansenula polymorpha
by: Wichittra Phimsen, et al.
Published: (2024-11-01) -
Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods
by: Shiwen Peng, et al.
Published: (2024-12-01) -
Correlation and prognosis analysis of human papillomavirus infection and P16 expression in oral and oropharyngeal squamous cell carcinomas
by: Yandie Lin, et al.
Published: (2025-04-01) -
Immunogenicity of Matrix Protein 2 Ectodomain (M2e) Displayed on Nodavirus-like Particles as Avian Influenza Vaccine for Poultry
by: Anis Suraya Mohamad Abir, et al.
Published: (2025-06-01)